[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

+1-877-825-3327

Email address

medicalinformation@tpna.com

Condition

Crohn Disease

Treatment type

Interventional

Investigational product

Adalimumab

Phase

Phase 4

Sponsor

Takeda

ClinicalTrials.gov identifier

NCT02764762

Study number

Vedolizumab-4006

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

The purpose of this study is to determine the effect of triple combination therapy with an anti-integrin (vedolizumab intravenous [IV]), a tumor necrosis factor (TNF) antagonist (adalimumab subcutaneously [SC]), and an immunomodulator (oral methotrexate) on endoscopic remission in participants with newly-diagnosed CD stratified at higher risk for complications.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria
Exclusion criteria
  1. GI) Exclusion Criteria 1. Has a diagnosis of ulcerative colitis (
  2. UC) or indeterminate colitis. 2. Has clinical evidence of a current abdominal abscess or a history of prior abdominal abscess. 3. Has a known perianal fistula with abscess. (The participant may have a perianal fistula without abscess.) 4. Has a known fistula (other than perianal fistula).

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site